Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections

Vaccine

Volumn 22, Issue 7, 2004, Pages 840-847

  Baumann, U ^a   Mansouri, E ^b   Von Specht, B U ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

OprF OprI; Pseudomonas aeruginosa

Indexed keywords

IMMUNOGLOBULIN; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN F; OUTER MEMBRANE PROTEIN I; PSEUDOMONAS VACCINE; RECOMBINANT PROTEIN; TETAGAM; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BLOOD SAMPLING; BURN INFECTION; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA; RAT; VACCINATION REACTION;

EID: 0842281535     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.029     Document Type: Conference Paper

References (70)

1. Gallagher P.G., Watanakunakorn Ch. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. Rev. Infect. Dis. 11:1989;846-852.
2. Gordon S.M., Serke J.M., Keys T.F., Ryan T., Fatica C.A., Schmitt S.K.et al. Secular trends in nosocomial bloodstream infections in a 55-bed cardiothoracic intensive care unit. Ann. Thorac. Surg. 65:1998;95-100.
3. Holder I.A. Pseudomonas immunotherapy. Serodiagn. Immunother. 2:1988;7-16.
4. Holzheimer R.G., Quoika P., Pätzmann D., Füssle R. Nosocomial infections in general surgery: surveillance report from a German University. Clin. Infect. 18:1990;219-225.
5. Pennington J.E., Pseudomonas aeruginosa pneumonia and other respiratory tract infections. In: Baltch A, editor. Pseudomonas aeruginosa infections and treatment. Marcel Dekker Inc., New York; 1994. p. 159-181.
6. McManus A.T., Mason A.D. Jr., McManus W.F., Pruitt B.A. Jr. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur. J. Clin. Microbiol. 4:1985;219-223.
7. Pruitt B.A. Jr., McManus A.T., Kim S.H., Goodwin C.W. Burn wound infections: current status. World J. Surg. 22:1998;135-145.
8. Pruitt B.A. Jr., Colonel M.C., McManus A.T. Opportunistic infections in severely burned patients. Am. J. Med. 30:1984;146-154.
9. Korvick J.A., Marsh J.W., Starzl T.E., Yu V.L. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery. 109:1991;62-68.
10. Griffith S.J., Nathan C., Selander R.K., Chamberlin W., Gordon St., Kabins S.et al. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. J. Infect. Dis. 160:1989;1030-1036.
11. Burns J.L., Gibson R.L., McNamara S., Yim D., Emerson J., Rosenfeld M.et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183:2001;44-452.
12. Hanberger H., Hoffmann M., Lindgren S., Nilson L.E. High incidence of antibiotic resistance among bacteria in 4 intensive care units at a university hospital in Sweden. Scand. J. Infect. Dis. 29:1997;602-614.
13. Hancock R.E.W. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 18:1986;653-656.
14. Hoiby N., Krogh J.H., Moser C., Song Z., Ciofu O., Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3:2001;23-35.
15. Hsueh P.R., Teng L.J., Chen Y.C., Ho S.W., Lu K.T. Persistence of a multidrug-resistance Pseudomonas aeruginosa clone in an intensive care burn unit. J. Clin. Microbiol. 2:1998;1347-1351.
16. Srikumar R., Kon T., Gotoh N., Poole K. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain. Antimicrob. Agents Chemother. 42:1988;65-71.
17. Tassios P.T., Gennimata V., Maniatis A.N., Fock C., Legakis N.J. Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas aeruginosa Study Group. J. Clin. Microbiol. 36:1998;897-901.
18. Hong Y.Q., Ghebrehiwet B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin. Immun. Immunopathol. 62:1992;1333-1338.
19. McGhee JR, Czerkinsky C, Mestecky J, Mucosal vaccines: an overview. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, editors. Mucosal immunology. Academic Press, San Diego; 1999.
20. Alexander J.W., Fisher M.W. Immunization against Pseudomonas infection after thermal injury. J. Infect. Dis. 130:1974;152-158.
21. Jones R.J., Roe E.A., Gupta J.L. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet. 2:1979;977-983.
22. Miller J.M., Spilsbury J.F., Jones R.J., Roe E.A., Lowbury E.J.L. A new polyvalent Pseudomonas vaccine. J. Med. Microbiol. 10:1977;19-27.
23. Cryz S.J. Jr., Sadoff C., Ohmann D., Fürer E. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J. Lab. Clin. Med. 111:1988;701-707.
24. Cryz S.J. Jr., Fürer E., Cross A.S., Wegmann A., Germanier R., Sadoff J.C. Safety and immunogenicity of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans. J. Clin. Invest. 80:1987;51-56.
25. Cryz S.J. Jr., Sadoff J.C., Fürer E. Octavalent Pseudomonas aeruginosa-O-polysaccharide-toxin A conjugate vaccine. Microb. Pathog. 6:1987;75-80.
26. Pier G.B. Safety and immunogenicity of high-molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. J. Clin. Invest. 69:1982;303-308.
27. Pier GB. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research. In: Speert DP, Hancock REW, editors. Pseudomonas aeruginosa: new therapeutic approaches from basic research, vol. 36. S. Karger, Basel, Switzerland; 1985. p. 157-67.
28. Pier G.B. Rational for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Behring Inst. Mitt. 98:1997;350-360.
29. Pier G.B., Des Jardin D., Grout M., Garner C., Bennet S.E., Pekoe G. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 62:1994;3972-3979.
30. Mutharia L.M., Nicas T.L., Hancock R.E.W. Outer membrane proteins of P. aeruginosa serotype strains. J. Infect. Dis. 146:1982;770-779.
31. von Specht B.U., Strigl G., Ehret W., Brendel W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection. 15:1987;408-412.
32. Cohen J. Naked DNA points way to vaccines. Science. 259:1993;1691-1692.
33. Donnelly J.J., Ulmer J.B., Liu M.A. Immunization with polynucleotides. Immunologist. 2:1994;20-26.
34. Price B.M., Barten Legutki J., Galloway D.R., von Specht B.U., Gilleland L.B., Gilleland H.E. Jr.et al. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 33:2002;89-99.
35. Kraehenbuhl J.P., Neutra M.R. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol. Rev. 72:1992;853-879.
36. Toth A., Schödel F., Duchêne M., Massarrat K., Blum B., Schmitt A.et al. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin. Vaccine. 12:1994;1215-1221.
37. Finke M., Muth G., Reichhelm T., Thoma M., Duchêne M., Hungerer K.D.et al. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies. Infect. Immun. 59:1991;1251-1254.
38. Finke M., Duchêne M., Eckhardt A., Domdey H., von Specht B.U. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect. Immun. 58:1990;2241-2244.
39. Gilleland H.E. Jr., Gilleland L.B., Matthews-Greer J.M. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in rats. Infect. Immun. 56:1988;1017-1022.
40. Gilleland H.E. Jr., Parker M.G., Matthew J.M., Berg R.D. Use of purified outer membrane protein F (porin) of Pseudomonas aeruginosa as a protective vaccine in mice. Infect. Immun. 44:1984;49-54.
41. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J. Infect. Dis. 155:1987;1282-1291.
42. von Specht B.U., Knapp B., Muth G., Bröker M., Hungerer K.D., Diehl K.D.et al. Protection of immunocompromised mice against lethal infection with P. aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect. Immun. 63:1995;1855-1861.
43. von Specht B.U., Strigl G., Ehret W., Brendel W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection. 15:1987;408-412.
44. Duchêne M., Schweizer A., Lottspeich F., Krauss G., Marget M., Vogel K.et al. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J. Bacteriol. 170:1988;155-162.
45. Duchêne M., Barron C., Schweizer A., von Specht B.U., Domdey H. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning sequence, and expression in Escherichia coli. J. Bacteriol. 171:1989;4130-4137.
46. Gabelsberger J., Knapp B., Bauernsachs S., Lenz U., von Specht B.U., Domdey H. A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa. Behring Inst. Mitt. 98:1997;302-314.
47. Gilleland H.E. Jr., Hughes E.E., Gilleland L.B., Matthews-Greer J.M., Staczek J. Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa. Curr. Microbiol. 31:1995;279-286.
48. Gilleland L.B., Gilleland H.E. Jr. Synthetic peptides representing two protective, linear B cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific. Infect. Immun. 63:1995;2347-2351.
49. Hancock R.E.W., Wong R. Potential of protein OprF of Pseudomonas in bivalent vaccines. Behring Inst. Mitt. 98:1997;283-290.
50. von Specht B.U., Gabelsberger J., Knapp B., Hundt E., Schmidt-Pilger H., Bauernsachs S.et al. Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections. J. Biotechnol. 83:2000;3-12.
51. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D.et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 67:1999;1461-1470.
52. Ausubel FM, Brent R, Kingston RE, Moore DD, Smith JA, Seidman JG, Struhl K.
53. Mansouri E, Blome-Eberwein S, Knapp B, Hungerer KD, Germann G, von Specht BU. Clinical study to assess the immunogenicity and tolerability of a recombinant Pseudomonas aeruginosa high efficiency transformation by electroporation. Curr Protocols Mol Biol 1997:1994-7.
54. Eckhardt A., Heiss M.M., Ehret E., Permanetter M., Duchêne M., Domdey H.et al. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay. Zbl Bakt. 275:1991;100-111.
55. OprF-OprI vaccine in burn patients. FEMS Immunol. Med. Microbiol. 2003;37:161-6.
56. Tobiasen J., Hiebert J., Edlich R. Prediction of burn mortality. Surg. Gynecol. Obstet. 154:1982;711-714.
57. Göcke K, Baumann U, Hagemann H, Gabelsberger J, Hahn H, Freihorst J, von Specht BU. Mucosal vaccination with a recombinant OprF-OprI vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol. Med. Microbiol. 2003;37.
58. Koch C., Hoiby N. Pathogenesis of cystic fibrosis. Lancet. 341:1993;1065.
59. Jung S.B., Ahn B.Y., Kim Y.H., Kim J.J., Kim D.K., Kim I.S.et al. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine. 18:2000;1952-1961.
60. Kim D.K., Kim J.J., Kim J.H., Woo Y.M., Kim S., Yoon D.W.et al. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine. 19:2000;1274-1283.
61. Johanson W.G.J., Woods D.E., Chaudhuri T. Association of respiratory tract colonization with adherence of gram-negative bacilli to epithelial cells. J. Infect. Dis. 139:1979;667.
62. Pilette C., Ouadriri Y., Godding V., Vaerman J.P., Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur. Respir. J. 18:2001;571-588.
63. Butcher E.C., Picke L.J. Lymphocyte homing and homeostasis. Science. 272:1996;60-66.
64. Kim K.J., Malik A.B. Protein transport across the lung epithelial barrier. Am. J. Physiol. Lung Cell Mol. Physiol. 84(2):2003;L247-259.
65. Quiding-Jabrink M., Nordstrom I., Granstrom G. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest. 99:1997;1281-1286.
66. Rudin A., Riise G.C., Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect. Immun. 67:1999;2884-2890.
67. Hvalbye B.K., Aaberge I.S., Lovik M., Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect. Immun. 67:1999;4320.
68. Muszkat M., Yehuda A.B., Schein M.H., Friedlander Y., Naveh P., Greenbaum E.et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J. Med. Virol. 61:2000;100-106.
69. Baumann U., Göcke K., Hagemann H., Freihorst J., von Specht B.U. Mucosal immune response after nasal and systemic vaccination with a recombinant outer membrane protein F and I of Pseudomonas aeruginosa in healthy volunteers. Pediatr. Pulmonol. Suppl. 24:2002;275.
70. Johanson W.G.J., Pierce A.K., Sanford J.P., Thomas G.D. Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract. Ann Intern. Med. 77:1972;701.